Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-03-02

AUTHORS

Mathieu Gauthé, Kevin Zarca, Cyrielle Aveline, Frédéric Lecouvet, Sona Balogova, Olivier Cussenot, Jean-Noël Talbot, Isabelle Durand-Zaleski

ABSTRACT

BackgroundThe diagnostic performance of 18F-sodium fluoride positron emission tomography/computed tomography (PET/CT) (NaF), 18F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared.MethodsWe performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule.ResultsThere was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental cost-effectiveness ratio of 3000€/QALY when imaging was interpreted by local specialists and 9000€/QALY when imaging was interpreted by experts.ConclusionsFCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.Trial registrationNCT01501630. Registered 29 December 2011. More... »

PAGES

25

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12880-020-00425-y

DOI

http://dx.doi.org/10.1186/s12880-020-00425-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1125329683

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32122345


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Choline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Decision Trees", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diffusion Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Markov Chains", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron Emission Tomography Computed Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium Fluoride", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia", 
          "id": "http://www.grid.ac/institutes/grid.7634.6", 
          "name": [
            "Nuclear Medicine, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, 4 rue de la Chine, 75020, Paris, France", 
            "AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France", 
            "Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gauth\u00e9", 
        "givenName": "Mathieu", 
        "id": "sg:person.01121730347.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121730347.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zarca", 
        "givenName": "Kevin", 
        "id": "sg:person.01033615220.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033615220.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, 4 rue de la Chine, 75020, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Nuclear Medicine, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, 4 rue de la Chine, 75020, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aveline", 
        "givenName": "Cyrielle", 
        "id": "sg:person.07401136226.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07401136226.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology, Institut de Recherche Exp\u00e9rimentale Et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium", 
          "id": "http://www.grid.ac/institutes/grid.48769.34", 
          "name": [
            "Radiology, Institut de Recherche Exp\u00e9rimentale Et Clinique, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lecouvet", 
        "givenName": "Fr\u00e9d\u00e9ric", 
        "id": "sg:person.01204666563.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204666563.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia", 
          "id": "http://www.grid.ac/institutes/grid.7634.6", 
          "name": [
            "Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Balogova", 
        "givenName": "Sona", 
        "id": "sg:person.0610535201.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610535201.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Urology, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Urology, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cussenot", 
        "givenName": "Olivier", 
        "id": "sg:person.013241233644.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013241233644.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, 4 rue de la Chine, 75020, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Nuclear Medicine, H\u00f4pital Tenon, AP-HP, Sorbonne Universit\u00e9, 4 rue de la Chine, 75020, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Talbot", 
        "givenName": "Jean-No\u00ebl", 
        "id": "sg:person.07715603712.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07715603712.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Public Health, H\u00f4pital Henri Mondor, AP-HP,Universit\u00e9 Paris 12, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France", 
            "Department of Public Health, H\u00f4pital Henri Mondor, AP-HP,Universit\u00e9 Paris 12, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Durand-Zaleski", 
        "givenName": "Isabelle", 
        "id": "sg:person.01327533357.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00345-018-2547-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107950852", 
          "https://doi.org/10.1007/s00345-018-2547-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00256-014-1903-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045392685", 
          "https://doi.org/10.1007/s00256-014-1903-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s003300050038", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038039327", 
          "https://doi.org/10.1007/s003300050038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12885-017-3922-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100234824", 
          "https://doi.org/10.1186/s12885-017-3922-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002560050434", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032633215", 
          "https://doi.org/10.1007/s002560050434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-018-4058-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104434761", 
          "https://doi.org/10.1007/s00259-018-4058-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-008-0788-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006843363", 
          "https://doi.org/10.1007/s00259-008-0788-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-03-02", 
    "datePublishedReg": "2020-03-02", 
    "description": "BackgroundThe diagnostic performance of 18F-sodium fluoride positron emission tomography/computed tomography (PET/CT) (NaF), 18F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared.MethodsWe performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule.ResultsThere was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental cost-effectiveness ratio of 3000\u20ac/QALY when imaging was interpreted by local specialists and 9000\u20ac/QALY when imaging was interpreted by experts.ConclusionsFCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.Trial registrationNCT01501630. Registered 29 December 2011.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12880-020-00425-y", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024948", 
        "issn": [
          "1471-2342"
        ], 
        "name": "BMC Medical Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "PET/CT", 
      "diffusion-weighted whole-body magnetic resonance imaging", 
      "bone metastases", 
      "biochemical recurrence", 
      "prostate cancer", 
      "diagnostic performance", 
      "metastatic castration-resistant prostate cancer", 
      "castration-resistant prostate cancer", 
      "fluoride PET/CT", 
      "whole-body magnetic resonance imaging", 
      "positron emission tomography/", 
      "previous definitive treatment", 
      "national cost study", 
      "incremental cost-effectiveness ratio", 
      "recurrent prostate cancer", 
      "emission tomography/", 
      "imaging modalities", 
      "prostate cancer patients", 
      "cost-effectiveness ratio", 
      "model-based economic evaluations", 
      "cost-effective imaging modality", 
      "magnetic resonance imaging", 
      "health states", 
      "diffusion-weighted MRI", 
      "cost-effectiveness analysis", 
      "definitive treatment", 
      "cancer patients", 
      "threshold incremental cost-effectiveness ratio", 
      "tomography/", 
      "hospital costs", 
      "economic evaluation", 
      "resonance imaging", 
      "metastasis", 
      "natural history", 
      "patients", 
      "cancer", 
      "CT", 
      "significant differences", 
      "recurrence", 
      "modalities", 
      "local specialists", 
      "incremental effect", 
      "ResultsThere", 
      "cost studies", 
      "QALY", 
      "MethodsWe", 
      "trials", 
      "MRI", 
      "specialists", 
      "death", 
      "tomography", 
      "treatment", 
      "evaluation", 
      "indications", 
      "FCH", 
      "imaging", 
      "schedule", 
      "differences", 
      "history", 
      "study", 
      "utility", 
      "effect", 
      "experts", 
      "combination", 
      "literature", 
      "PCA", 
      "real cost", 
      "sites", 
      "detection", 
      "ratio", 
      "comparison", 
      "analysis", 
      "Markov model", 
      "cost", 
      "state", 
      "France", 
      "decision tree", 
      "reading", 
      "technique", 
      "probability", 
      "model", 
      "performance", 
      "cost schedule", 
      "trees", 
      "state transition probabilities"
    ], 
    "name": "Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France", 
    "pagination": "25", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1125329683"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12880-020-00425-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32122345"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12880-020-00425-y", 
      "https://app.dimensions.ai/details/publication/pub.1125329683"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_873.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12880-020-00425-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12880-020-00425-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12880-020-00425-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12880-020-00425-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12880-020-00425-y'


 

This table displays all metadata directly associated to this object as RDF triples.

319 TRIPLES      21 PREDICATES      137 URIs      121 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12880-020-00425-y schema:about N094de4fd2e194812b72e6dcf80d16cdf
2 N11a7de7dd9934bb791395ace96c81db6
3 N1926b3abb96542f58d61bf15db807155
4 N66150d0b91a342db81bf44e2f7c289e8
5 N686f8a8a98cf4bed8c14fc0d98b44c8f
6 N7124d4290a5742f2b20204d926a8be1b
7 N756305140fd54ac1aff0fb054db7035a
8 N8499d766aafa48d3a97bef078b61820b
9 Na8353da1d61642fabf8583111c6d0c28
10 Na938bdc1c18748de849d135eeb290f5d
11 Nafdbccfe7380494e9b54ae536039fa10
12 Nbfc7bf03949848d38b8a9401d63dc246
13 Nc1cebd23909445b790e8aad3f7113a78
14 Nc41d0ed9bbb94857884e5dce9869a86e
15 Nc99b306edf4149f5818aef620683b6e7
16 Ndcf6f3a06fb14bfcaae1629ee37d7288
17 Ne0929710dd7e4f00b88149b103c29480
18 Ne4f7f87426a94378997b9a8337bfeb37
19 Nf090bb5066424e5884dbffe8b0b5a624
20 anzsrc-for:11
21 anzsrc-for:1103
22 anzsrc-for:1112
23 schema:author N743436b283c94edebf685d5b6fb4512b
24 schema:citation sg:pub.10.1007/s00256-014-1903-9
25 sg:pub.10.1007/s002560050434
26 sg:pub.10.1007/s00259-008-0788-z
27 sg:pub.10.1007/s00259-018-4058-4
28 sg:pub.10.1007/s003300050038
29 sg:pub.10.1007/s00345-018-2547-5
30 sg:pub.10.1186/s12885-017-3922-0
31 schema:datePublished 2020-03-02
32 schema:datePublishedReg 2020-03-02
33 schema:description BackgroundThe diagnostic performance of 18F-sodium fluoride positron emission tomography/computed tomography (PET/CT) (NaF), 18F-fluorocholine PET/CT (FCH) and diffusion-weighted whole-body magnetic resonance imaging (DW-MRI) in detecting bone metastases in prostate cancer (PCa) patients with first biochemical recurrence (BCR) has already been published, but their cost-effectiveness in this indication have never been compared.MethodsWe performed trial-based and model-based economic evaluations. In the trial, PCa patients with first BCR after previous definitive treatment were prospectively included. Imaging readings were performed both on-site by local specialists and centrally by experts. The economic evaluation extrapolated the diagnostic performances of the imaging techniques using a combination of a decision tree and Markov model based on the natural history of PCa. The health states were non-metastatic and metastatic BCR, non-metastatic and metastatic castration-resistant prostate cancer and death. The state-transition probabilities and utilities associated with each health state were derived from the literature. Real costs were extracted from the National Cost Study of hospital costs and the social health insurance cost schedule.ResultsThere was no significant difference in diagnostic performance among the 3 imaging modalities in detecting bone metastases. FCH was the most cost-effective imaging modality above a threshold incremental cost-effectiveness ratio of 3000€/QALY when imaging was interpreted by local specialists and 9000€/QALY when imaging was interpreted by experts.ConclusionsFCH had a better incremental effect on QALY, independent of imaging reading and should be preferred for detecting bone metastases in patients with biochemical recurrence of prostate cancer.Trial registrationNCT01501630. Registered 29 December 2011.
34 schema:genre article
35 schema:isAccessibleForFree true
36 schema:isPartOf N9a271ee5fe6d4b759564b5070e9d198b
37 Na7e3a5eedc5848e2891189277d7344d0
38 sg:journal.1024948
39 schema:keywords CT
40 FCH
41 France
42 MRI
43 Markov model
44 MethodsWe
45 PCA
46 PET/CT
47 QALY
48 ResultsThere
49 analysis
50 biochemical recurrence
51 bone metastases
52 cancer
53 cancer patients
54 castration-resistant prostate cancer
55 combination
56 comparison
57 cost
58 cost schedule
59 cost studies
60 cost-effective imaging modality
61 cost-effectiveness analysis
62 cost-effectiveness ratio
63 death
64 decision tree
65 definitive treatment
66 detection
67 diagnostic performance
68 differences
69 diffusion-weighted MRI
70 diffusion-weighted whole-body magnetic resonance imaging
71 economic evaluation
72 effect
73 emission tomography/
74 evaluation
75 experts
76 fluoride PET/CT
77 health states
78 history
79 hospital costs
80 imaging
81 imaging modalities
82 incremental cost-effectiveness ratio
83 incremental effect
84 indications
85 literature
86 local specialists
87 magnetic resonance imaging
88 metastasis
89 metastatic castration-resistant prostate cancer
90 modalities
91 model
92 model-based economic evaluations
93 national cost study
94 natural history
95 patients
96 performance
97 positron emission tomography/
98 previous definitive treatment
99 probability
100 prostate cancer
101 prostate cancer patients
102 ratio
103 reading
104 real cost
105 recurrence
106 recurrent prostate cancer
107 resonance imaging
108 schedule
109 significant differences
110 sites
111 specialists
112 state
113 state transition probabilities
114 study
115 technique
116 threshold incremental cost-effectiveness ratio
117 tomography
118 tomography/
119 treatment
120 trees
121 trials
122 utility
123 whole-body magnetic resonance imaging
124 schema:name Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France
125 schema:pagination 25
126 schema:productId N008dec7e819149caa264437715817c00
127 N03c4574021064a4596cf0f12a001650c
128 Nc5aa89922d164507863f36bcec966e81
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125329683
130 https://doi.org/10.1186/s12880-020-00425-y
131 schema:sdDatePublished 2022-10-01T06:47
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher Nb25e51a5e5b04ed0b42a81319fcf082f
134 schema:url https://doi.org/10.1186/s12880-020-00425-y
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N008dec7e819149caa264437715817c00 schema:name doi
139 schema:value 10.1186/s12880-020-00425-y
140 rdf:type schema:PropertyValue
141 N03c4574021064a4596cf0f12a001650c schema:name dimensions_id
142 schema:value pub.1125329683
143 rdf:type schema:PropertyValue
144 N08572933116d4ad7bcef0f0e5b8d964d rdf:first sg:person.01033615220.30
145 rdf:rest N0a81fccdeb804d24859e9fefbdd35b5d
146 N094de4fd2e194812b72e6dcf80d16cdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Choline
148 rdf:type schema:DefinedTerm
149 N0a81fccdeb804d24859e9fefbdd35b5d rdf:first sg:person.07401136226.60
150 rdf:rest N8614f47ec8724e729cdde8225023cb72
151 N11a7de7dd9934bb791395ace96c81db6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Neoplasm Recurrence, Local
153 rdf:type schema:DefinedTerm
154 N1926b3abb96542f58d61bf15db807155 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Prostatic Neoplasms
156 rdf:type schema:DefinedTerm
157 N267a349204d34756b0cb5432518830bd rdf:first sg:person.07715603712.83
158 rdf:rest N8cb5503de220434b85a74f65e110412d
159 N66150d0b91a342db81bf44e2f7c289e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Models, Economic
161 rdf:type schema:DefinedTerm
162 N686f8a8a98cf4bed8c14fc0d98b44c8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 N7124d4290a5742f2b20204d926a8be1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Sensitivity and Specificity
167 rdf:type schema:DefinedTerm
168 N743436b283c94edebf685d5b6fb4512b rdf:first sg:person.01121730347.36
169 rdf:rest N08572933116d4ad7bcef0f0e5b8d964d
170 N756305140fd54ac1aff0fb054db7035a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cost-Benefit Analysis
172 rdf:type schema:DefinedTerm
173 N8499d766aafa48d3a97bef078b61820b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Markov Chains
175 rdf:type schema:DefinedTerm
176 N8614f47ec8724e729cdde8225023cb72 rdf:first sg:person.01204666563.57
177 rdf:rest Ne1a712bf6beb4df7a500839fbda1755a
178 N8cb5503de220434b85a74f65e110412d rdf:first sg:person.01327533357.46
179 rdf:rest rdf:nil
180 N9a271ee5fe6d4b759564b5070e9d198b schema:volumeNumber 20
181 rdf:type schema:PublicationVolume
182 Na7e3a5eedc5848e2891189277d7344d0 schema:issueNumber 1
183 rdf:type schema:PublicationIssue
184 Na8353da1d61642fabf8583111c6d0c28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Sodium Fluoride
186 rdf:type schema:DefinedTerm
187 Na938bdc1c18748de849d135eeb290f5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Aged, 80 and over
189 rdf:type schema:DefinedTerm
190 Na9dec7ae128546c99c6c225bfbc41729 rdf:first sg:person.013241233644.08
191 rdf:rest N267a349204d34756b0cb5432518830bd
192 Nafdbccfe7380494e9b54ae536039fa10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Positron Emission Tomography Computed Tomography
194 rdf:type schema:DefinedTerm
195 Nb25e51a5e5b04ed0b42a81319fcf082f schema:name Springer Nature - SN SciGraph project
196 rdf:type schema:Organization
197 Nbfc7bf03949848d38b8a9401d63dc246 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Prospective Studies
199 rdf:type schema:DefinedTerm
200 Nc1cebd23909445b790e8aad3f7113a78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Bone Neoplasms
202 rdf:type schema:DefinedTerm
203 Nc41d0ed9bbb94857884e5dce9869a86e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Middle Aged
205 rdf:type schema:DefinedTerm
206 Nc5aa89922d164507863f36bcec966e81 schema:name pubmed_id
207 schema:value 32122345
208 rdf:type schema:PropertyValue
209 Nc99b306edf4149f5818aef620683b6e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Aged
211 rdf:type schema:DefinedTerm
212 Ndcf6f3a06fb14bfcaae1629ee37d7288 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Diffusion Magnetic Resonance Imaging
214 rdf:type schema:DefinedTerm
215 Ne0929710dd7e4f00b88149b103c29480 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Decision Trees
217 rdf:type schema:DefinedTerm
218 Ne1a712bf6beb4df7a500839fbda1755a rdf:first sg:person.0610535201.69
219 rdf:rest Na9dec7ae128546c99c6c225bfbc41729
220 Ne4f7f87426a94378997b9a8337bfeb37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name France
222 rdf:type schema:DefinedTerm
223 Nf090bb5066424e5884dbffe8b0b5a624 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Male
225 rdf:type schema:DefinedTerm
226 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
227 schema:name Medical and Health Sciences
228 rdf:type schema:DefinedTerm
229 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
230 schema:name Clinical Sciences
231 rdf:type schema:DefinedTerm
232 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
233 schema:name Oncology and Carcinogenesis
234 rdf:type schema:DefinedTerm
235 sg:journal.1024948 schema:issn 1471-2342
236 schema:name BMC Medical Imaging
237 schema:publisher Springer Nature
238 rdf:type schema:Periodical
239 sg:person.01033615220.30 schema:affiliation grid-institutes:grid.50550.35
240 schema:familyName Zarca
241 schema:givenName Kevin
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033615220.30
243 rdf:type schema:Person
244 sg:person.01121730347.36 schema:affiliation grid-institutes:grid.7634.6
245 schema:familyName Gauthé
246 schema:givenName Mathieu
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121730347.36
248 rdf:type schema:Person
249 sg:person.01204666563.57 schema:affiliation grid-institutes:grid.48769.34
250 schema:familyName Lecouvet
251 schema:givenName Frédéric
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204666563.57
253 rdf:type schema:Person
254 sg:person.013241233644.08 schema:affiliation grid-institutes:None
255 schema:familyName Cussenot
256 schema:givenName Olivier
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013241233644.08
258 rdf:type schema:Person
259 sg:person.01327533357.46 schema:affiliation grid-institutes:grid.412116.1
260 schema:familyName Durand-Zaleski
261 schema:givenName Isabelle
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327533357.46
263 rdf:type schema:Person
264 sg:person.0610535201.69 schema:affiliation grid-institutes:grid.7634.6
265 schema:familyName Balogova
266 schema:givenName Sona
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610535201.69
268 rdf:type schema:Person
269 sg:person.07401136226.60 schema:affiliation grid-institutes:None
270 schema:familyName Aveline
271 schema:givenName Cyrielle
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07401136226.60
273 rdf:type schema:Person
274 sg:person.07715603712.83 schema:affiliation grid-institutes:None
275 schema:familyName Talbot
276 schema:givenName Jean-Noël
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07715603712.83
278 rdf:type schema:Person
279 sg:pub.10.1007/s00256-014-1903-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045392685
280 https://doi.org/10.1007/s00256-014-1903-9
281 rdf:type schema:CreativeWork
282 sg:pub.10.1007/s002560050434 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032633215
283 https://doi.org/10.1007/s002560050434
284 rdf:type schema:CreativeWork
285 sg:pub.10.1007/s00259-008-0788-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1006843363
286 https://doi.org/10.1007/s00259-008-0788-z
287 rdf:type schema:CreativeWork
288 sg:pub.10.1007/s00259-018-4058-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104434761
289 https://doi.org/10.1007/s00259-018-4058-4
290 rdf:type schema:CreativeWork
291 sg:pub.10.1007/s003300050038 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038039327
292 https://doi.org/10.1007/s003300050038
293 rdf:type schema:CreativeWork
294 sg:pub.10.1007/s00345-018-2547-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107950852
295 https://doi.org/10.1007/s00345-018-2547-5
296 rdf:type schema:CreativeWork
297 sg:pub.10.1186/s12885-017-3922-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100234824
298 https://doi.org/10.1186/s12885-017-3922-0
299 rdf:type schema:CreativeWork
300 grid-institutes:None schema:alternateName Nuclear Medicine, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, 75020, Paris, France
301 Urology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
302 schema:name Nuclear Medicine, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, 75020, Paris, France
303 Urology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
304 rdf:type schema:Organization
305 grid-institutes:grid.412116.1 schema:alternateName Department of Public Health, Hôpital Henri Mondor, AP-HP,Université Paris 12, Créteil, France
306 schema:name AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France
307 Department of Public Health, Hôpital Henri Mondor, AP-HP,Université Paris 12, Créteil, France
308 rdf:type schema:Organization
309 grid-institutes:grid.48769.34 schema:alternateName Radiology, Institut de Recherche Expérimentale Et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
310 schema:name Radiology, Institut de Recherche Expérimentale Et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
311 rdf:type schema:Organization
312 grid-institutes:grid.50550.35 schema:alternateName AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France
313 schema:name AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France
314 rdf:type schema:Organization
315 grid-institutes:grid.7634.6 schema:alternateName Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia
316 schema:name AP-HP Health Economics Research Unit, INSERM UMR 1153, Paris, France
317 Nuclear Medicine, Faculty of Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia
318 Nuclear Medicine, Hôpital Tenon, AP-HP, Sorbonne Université, 4 rue de la Chine, 75020, Paris, France
319 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...